Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Reproductive Care in Women with Sickle Cell Disease - Use of Secondary Data to Investigate Risk of Contraception-Related Thrombosis and the Impact of Hydroxyurea on Pregnancy Outcomes

Award Number: R21HL150487
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/10/2020
PERIOD OF PERFORMANCE END DATE: 12/31/2022

Group Awards By:

View Award Description

Reproductive Care in Women with Sickle Cell Disease - Use of Secondary Data to Investigate Risk of Contraception-Related Thrombosis and the Impact of Hydroxyurea on Pregnancy Outcomes - PROJECT SUMMARY / ABSTRACT As medical advances improve morbidity and mortality in sickle cell disease (SCD), improving reproductive health is of increasing importance. Knowledge gaps include limited safety information for hormonal contraception and the impact of pre-pregnancy hydroxyurea (HU) use on pregnancy outcomes. Estrogen-containing contraceptives increase the risk of thromboembolism (TE), and there is little evidence on the safety of progestin-only contraceptives for women with SCD. Lack of safety data can be a barrier to provision of contraception for medically complex women. This is a particular concern for women with SCD, given the increased risk of mortality and morbidity during pregnancy, and the high rates of unplanned pregnancy. During pregnancy, women with SCD have increased risk of mortality, preeclampsia, and preterm delivery compared to race-matched peers. However, most of these data are 10-25 years old, when use of HU, a highly efficacious disease modifying therapy, was substantially lower. While the impact of HU on outcomes such as vaso-occlusive crises and acute chest syndrome is well described, the impact of pre-pregnancy HU use on pregnancy outcomes is unexplored. The objective of this R21 application is to combine our methodologic experience in large database research and our content expertise in women’s hematology and SCD to utilize health claims data to study contraception safety and pregnancy outcomes in women with SCD. The specific aims of this application are: 1) compare safety of contraceptive choices among women with SCD by identifying the hazard rate of TE in women prescribed progestin-only, estrogen-containing, or no hormonal contraception, and 2) compare pregnancy outcomes in women with SCD with and without HU exposure pre-pregnancy, and outcomes in women with SCD compared to age and race-matched controls. We hypothesize that time to TE in women using progestin-only contraception will be non-inferior to time to TE in women not using contraception, independent of age or SCD severity. We also hypothesize that pregnancy complications will be higher in women without HU use pre-pregnancy, again controlling for age and SCD severity. Finally, we hypothesize that current relative risks of preeclampsia and pre- term delivery in women with SCD compared to controls will be significantly lower compared to historical data. The proposed work is innovative because it addresses questions that have either not been studied (impact of pre-pregnancy HU exposure on clinical outcomes) or studied only in very small cohorts (contraception safety). Completion of this award will yield the following expected outcomes: 1) knowledge of the absolute risk of contraception-related TE in SCD and identification of the safest forms of contraception, and 2) demonstration of the impact of pre-pregnancy HU use on pregnancy outcomes. The proposed work is significant because understanding contraception safety is the first step to eliminating barriers to counseling and prescribing to a patient population with increased risks of adverse pregnancy outcomes. As well, better understanding of the impact of pre-pregnancy HU use on pregnancy may be key in promoting use of and adherence to HU.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$91 )
2024	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Blood Diseases and Resources Research	000	2	10/23/2023	NON-COMPETING CONTINUATION	-$91
														Subtotal = -$91

Issue Date FY: 2021 ( Subtotal = $115,507 )
2021	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Blood Diseases and Resources Research	002	2	5/25/2021	NON-COMPETING CONTINUATION	$11,551
2021	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Blood Diseases and Resources Research	001	2	12/23/2020	NON-COMPETING CONTINUATION	$103,956
2021	2020	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Blood Diseases and Resources Research	000	1	10/22/2020	NEW	$0
														Subtotal = $115,507

Issue Date FY: 2020 ( Subtotal = $127,197 )
2020	2020	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Blood Diseases and Resources Research	000	1	2/3/2020	NEW	$127,197
														Subtotal = $127,197

Grand Total All Awards = $242,613

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Reproductive Care in Women with Sickle Cell Disease - Use of Secondary Data to Investigate Risk of Contraception-Related Thrombosis and the Impact of Hydroxyurea on Pregnancy Outcomes

Award Number: R21HL150487

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/10/2020

PERIOD OF PERFORMANCE END DATE: 12/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer